Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

15Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

De Laere, B., Rajan, P., Grönberg, H., Dirix, L., & Lindberg, J. (2019, July 1). Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology. American Medical Association. https://doi.org/10.1001/jamaoncol.2019.0869

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free